metricas
covid
Buscar en
Clinics
Toda la web
Inicio Clinics Clinical and cytogenetic aspects of giant cell tumor of the sternum
Journal Information
Vol. 66. Issue 8.
Pages 1501-1504 (August 2011)
Share
Share
Download PDF
More article options
Vol. 66. Issue 8.
Pages 1501-1504 (August 2011)
CASE REPORT
Open Access
Clinical and cytogenetic aspects of giant cell tumor of the sternum
Visits
650
Edgard Eduard EngelI,
Corresponding author
engel@fmrp.usp.br

Tel.: 55 16 3602-2416
, Marcello Henrique Nogueira-BarbosaII, Maurício Eiji de Almeida Santos YamashitaIII, Federico Enrique Garcia CiprianoIV, Elvis Terci ValeraV, Maria Sol BrassescoV
I Faculty of Medicine of Ribeirão Preto, University of São Paulo - Department of Orthopedics and Traumatology, Ribeirão Preto/SP, Brazil.
II Faculty of Medicine of Ribeirão Preto, University of São Paulo - Division of Diagnostic Imaging, Department of Internal Medicine, Ribeirão Preto/SP, Brazil.
III Faculty of Medicine of Ribeirão Preto, University of São Paulo - Department of Pathology, Ribeirão Preto/SP, Brazil.
IV Faculty of Medicine of Ribeirão Preto, University of São Paulo - Department of Surgery, Ribeirão Preto/SP, Brazil.
V Faculty of Medicine of Ribeirão Preto, University of São Paulo - Division of Pediatric Oncology, Department of Pediatrics, Ribeirão Preto/SP, Brazil.
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Full Text
INTRODUCTION

Giant cell tumor (GCT) is a benign, locally aggressive bone tumor that usually affects the metaphysis and the epiphysis of long tubular bones. It is most frequently located around the knee. It is commonly diagnosed in patients between the ages of 20 and 45 years.1 GCT metastasizes merely to the lungs in 2% of cases with unpredictable behavior.

The sternum is infrequently affected by bone tumors. Although uncommon, malignant neoplasms, such as chondrosarcoma, osteosarcoma, myeloma, and lymphoma, are most likely to occur in this location.2 GCT of the sternum is an even rarer condition,3,4 and only seven cases are well documented in the literature.5–11 The present article describes the clinical and cytogenetic aspects of an additional case of GCT of the sternum occurring in a young male and includes a discussion of the surgical treatment.

Case Report

A 32-year-old man presented with a sternal mass that had shown progressive growth toward the suprasternal notch over the previous ten months. He complained of local pain that radiated to the cervical region and shoulders. Physical examination showed a bony, tender, six cm large mass of the manubrium (Figure 1A). The patient's pain was increased by palpation and elevation of his arms.

Figure 1.

A) Clinical aspect before and after surgery; B) intraoperative aspect after sternum resection; C) intraoperative aspect after reconstruction; and D) CT sagittal reconstruction showing anterior focal cortical bone destruction and soft tissue extension (arrow). In the post-contrast image, it is also possible to identify a small region without contrast enhancement (arrowhead). E) Axial T2-weighted MRI revealed intermediate signal intensity predominance in the sternum giant cell tumor (arrow), although regions of high signal intensity were also present (arrowhead).

(0.09MB).

Plain radiographs showed an expansile osteolytic lesion of the sternum. Computed tomography (CT) and magnetic resonance imaging (MRI) demonstrated focal cortical bone destruction, soft tissue extension and subchondral extension in relation to the sternoclavicular joints. CT images confirmed the osteolytic nature of the tumor and the absence of internal mineralization. Post-contrast CT and MRI demonstrated small foci that lacked the enhancement consistent with cystic or hemorrhagic areas. MRI showed that the lesion was of intermediate signal intensity on T1- and T2-weighted images and included additional areas of high signal intensity on the T2-weighted images (Figure 1D-E).

Histology from a prior biopsy performed at an outside institution revealed a benign tumor composed of multinucleated giant cells compatible with a GCT or a brown tumor of hyperparathyroidism. Laboratory evaluation revealed normal levels of calcium (1.25 MMol/l) and parathyroid hormone (21 PG/ml), making the diagnosis of a brown tumor highly unlikely.

The patient underwent resection of the manubrium with wide margins and post-resection reconstruction with GORE® DUALMESH® PLUS Biomaterial (W. L. Gore & Associates, Inc., Flagstaff, USA) mesh fixed with polyester separated stitches. Both the clavicles and the first ribs were fixed to the mesh. Thoracic inspection showed no mediastinal or lung nodules. Disarticulation of the body-manubrium joint was uneventful. A bilateral pectoralis major flap covered the mesh and allowed skin closure (Figure 1B-C).

Histological analysis of the resected specimen revealed the presence of multinucleated giant cells, mononucleated small cells and spindle cells with elongated nuclei without atypias. Occasionally, more than 100 nuclei could be perceived in the giant cells, a typical characteristic of GCT (Figure 2A).

Figure 2.

A-D) Histological aspect of the lesion showing a triphasic aspect with giant, mononuclear and fusiform cells (B), bone (C) and soft tissue (D) invasion of the tumor, and cystic formations (H&E, A - 400×, B - 200×, C - 100×, D - 100×); E) Cytogenetic analysis of a GCT sample showing a 51, XY, −7, +9, del(10)(q23), add(11)(p15)×2, −15, add(18)(q23), +mar1, +mar2×2, +mar3, +mar4, +mar5 karyotype.

(0.16MB).

The tumor growth had induced extensive bone erosion and focally infiltrated adjacent soft tissues (Figure 2B-C). Blood-filled dilated spaces were seen, suggesting an association with an aneurysmal bone cyst (Figure 2D). Less than one typical mitotic figure was seen per ten high power fields. Atypical mitosis, vascular invasion, and tumor necrosis were not detected.

To allow for cytogenetic studies, a fresh GCT sample (adjacent to areas of the tumor verified by frozen section) was aseptically collected in the operating room and processed as previously described.12 Cytogenetic analysis was performed on 30 metaphases and showed a complex complement characterized by the presence of numerous marker chromosomes. The karyotype was denoted as 51, XY, -7, +9, del(10)(q23), add(11)(p15)x2, -15, add(18)(q23), +mar1, +mar2×2, +mar3, +mar4, +mar5 (Figure 2E).

DISCUSSION

In the seven previously presented cases and this additional case, the median age of diagnosis is 48 years (range: 28 to 74 years); this age is slightly higher than that of GCT patients in general (Table 1).

Table 1.

Reported cases of giant cell tumor (GCT) of the sternum.

Reference  Gender  Age (years)  Symptom  Location  Size (cm)  Surgery  Reconstruction  Follow-up (months)  Cytogenetic study 
Sundaram et al., 1982  55  painless  manubrium  NA  subtotal sternectomy  none  NA  No 
Bay et al., 1999  49  pain  manubrium  3.9×3.2  subtotal sternectomy  prosthesis  60  Yes 
Segawa et al., 2004  55  pain  body  3.5×3.0  curretage  PMMA  12  No 
Imai et al., 2006  45  pain  body  8.5×4.5×2.5  subtotal sternectomy  prosthesis  12  No 
Futani et al., 2008  53  pain  body  8×4×2.5  curretage  PMMA  84  No 
Abate et al., 2009  28  painful mass  body  6.4×4.3×4.4  subtotal sternectomy  prosthesis  No 
Faria et al., 2010  74  painful mass  body  12×7.5×4.5  subtotal sternectomy  fascia lata  No 
Current case  32  painful mass  manubrium  7,6×5,1×4,7  subtotal sternectomy  Gore Dualmesh Plus®  10  Yes 

Abbreviations: NA, data not available; PMMA, bone cement filling.

Although imaging can strongly indicate GCT, a biopsy is necessary for diagnosis. Biopsy is of particular importance when the neoplasm affects an unusual location. The variety of giant cell-containing bone tumors (including osteosarcoma, chondroblastoma, and aneurysmal bone cysts) can cause biopsies with small sampling or fine-needle aspirations to be misleading.10 Even with larger tumor samples, it may be difficult to distinguish between GCT and parathyroid brown tumor, and it is necessary to examine specific hormone, calcium, and phosphate serum levels.

There is no consensus regarding the optimal surgical treatment of sternal GCT; interventions ranging from simple curettage to wide resection have been proposed.9 Futani et al. suggest that the initial treatment should involve extended curettage followed by filling with bone cement (Polimetilmetacrilate - PMMA). Because local recurrence rates reach approximately 50% due to the locally aggressive behavior of GCTs, more aggressive forms of surgery, such as marginal or wide resection, should be considered.8,9

Futani et al. suggest that a prosthetic replacement is needed after a subtotal sternectomy to protect the lungs, heart, and main vessels as well as to restore functional thoracic movement to prevent paradoxical respiration.9 As described by Gonfiotti et al., we did not use a rigid prosthetic replacement after the partial sternectomy. No respiratory distress was observed in our patient.13

Three of the eight described cases affected the manubrium and were treated by subtotal sternectomy. Reconstructions were performed with prosthetics in one case, with nothing in one case and with a mesh in our case. In the five cases that affected the body of the sternum, two were treated with curettage and PMMA filling and three with subtotal sternectomy and reconstruction (with a prosthesis in two cases and fascia lata in one) (Table 1).

There are only limited data in the literature on chromosomal aberrations in GCT of the bone. Typically, this tumor is characterized by a high frequency of telomeric fusion, which has been implicated in the initiation of chromosomal instability and tumorigenesis.14 Correspondingly, GTG-banding analysis has demonstrated a more frequent involvement of chromosomes 11p, 13p, 15p, 18p, 19p, and 21p in this process.15

Cytogenetic analysis of our sample showed a complex karyotype characterized by the presence of clonal rearrangements and numerous marker chromosomes. In the literature, some clonal aberrations have been described.15–17 Most notably, Bridge et al. demonstrated clonal structural translocations involving 11p15 in more than one patient; this region was also affected in our tumor sample.15 Sawyer et al. described abnormal karyotypes with clonal telomeric fusions involving the short arm of chromosome 11.18 In three of the five cases studied, telomeric fusions of 11pter were apparently the precursor lesions to the progression of sub-clones of 11p with structural chromosomal aberrations.

Sternal GCT is a very rare disease and should be treated with partial sternectomy. Reconstruction may be done with rigid or flexible materials depending on the stability of the chest wall. Biopsy is indispensable, and the ability to differentiate between GCT and hyperparathyroidism depends on blood sampling. Although no association has been established between unfavorable outcomes and chromosomal changes other than telomeric associations, the frequent involvement of 11p15 in clonal rearrangements suggests that chromosomal changes play an important role in GCT initiation and progression. Whether this alteration is associated with this particular tumor location requires further investigation.

REFERENCES
[1]
R Reid , SS Banerjee , S Sciot .
Giant cell tumor in.
World health organization classification of tumors. Pathology and genetics of tumors of soft tissue and bone. 1st ed, pp. p.234-p.236
[2]
RJ Downey , AG Huvos , N Martini .
Primary and secondary malignancies of the sternum.
Semin Thorac Cardiovasc Surg, 11 (1999), pp. 293-296
[3]
M Campanacci , N Baldini , S Boriani , A Sudanese .
Giant cell tumor of bone.
J Bone Joint Surg Am, 69 (1987), pp. 106-114
[4]
M Campanacci .
Giant cell tumor.
Bone and soft tissue tumors. 2nd ed, pp. p.99
[5]
M Sundaram , SA Martin , FE Johnson , MK Wolverson .
Case report 198.
Giant cell tumor of manubrium. Skeletal Radiol, 8 (1982), pp. 225-227
[6]
JO Bay , YJ Bignon , P Gros , R Jancovici , F Desangles , P Dubayle , et al.
Giant cell tumor of the sternum. Report of a case with a 17q isochromosome.
Rev Rhum Engl Ed, 66 (1999), pp. 49-52
[7]
T Segawa , M Kanamori , K Ohmori , M Nobukiyo , S Nogami , T Kimura , et al.
Giant cell tumor of the sternum: a case report.
[8]
K Imai , Y Minamiya , H Saito , H Kawai , M Ito , J Ogawa .
Giant cell tumor of the sternum.
Jpn J Thorac Cardiovasc Surg, 54 (2006), pp. 405-408
[9]
H Futani , Y Okumura , Y Fukuda , S Fukunaga , S Hasegawa , S Yoshiya .
Giant cell tumor of the sternum: a case report and review of the literature.
Anticancer Res, 28 (2008), pp. 4117-4120
[10]
E Abate , F Banki , JA Hagen , N Klipfel .
Giant cell tumor of the sternum.
[11]
RA Faria , CM Silva , JEA Miziara , FY Melo , SRM Silva , CR Viana .
Giant cell tumor of the sternum.
[12]
MS Brassesco , ET Valera , L Neder , AM Castro-Gamero , D Arruda , HR Machado , et al.
Polyploidy in atypical grade II choroid plexus papilloma of the posterior fossa, 29 (2009), pp. 293-298
[13]
A Gonfiotti , PF Santini , D Campanacci , M Innocenti , S Ferrarello , A Caldarella , et al.
Malignant primary chest-wall tumours: techniques of reconstruction and survival.
[14]
MH Zheng , P Siu , JM Papadimitriou , DJ Wood , AR Murch .
Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone.
[15]
JA Bridge , JR Neff , BJ Mouron .
Giant cell tumor of bone.
Chromosomal analysis of 48 specimens and review of the literature. Cancer Genet Cytogenet, 58 (1992), pp. 2-13
[16]
WM Molenaar , E Van den Berg , AC Dolfin , H Zorgdrager , HJ Hoekstra .
Cytogenetics of fine needle aspiration biopsies of sarcomas.
[17]
R Sciot , H Dorfman , P Brys , P Dal Cin , I De Wever , CD Fletcher , et al.
Cytogenetic-morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions.
A report from the CHAMP study group. Mod Pathol, 13 (2000), pp. 1206-1210
[18]
JR Sawyer , LS Goosen , RL Binz , CM Swanson , RW Nicholas .
Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone.
Copyright © 2011. CLINICS
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos